Co-Diagnostics (CODX) Projected to Post Earnings on Thursday

Co-Diagnostics (NASDAQ:CODX) is projected to post its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect Co-Diagnostics to announce earnings of ($1.25) per share and revenue of $0.17 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:30 PM ET.

Co-Diagnostics (NASDAQ:CODX) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($1.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.00) by $1.54. The firm had revenue of $0.17 million during the quarter, compared to the consensus estimate of $0.13 million. Co-Diagnostics had a negative return on equity of 210.99% and a negative net margin of 6,531.77%.

Co-Diagnostics Price Performance

NASDAQ CODX opened at $0.36 on Thursday. The firm has a market capitalization of $3.19 million, a P/E ratio of -0.04 and a beta of 3.15. Co-Diagnostics has a 1-year low of $0.35 and a 1-year high of $13.54. The business’s 50-day simple moving average is $0.93 and its 200-day simple moving average is $2.17.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on CODX. Maxim Group raised shares of Co-Diagnostics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 18th. Weiss Ratings upgraded shares of Co-Diagnostics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, October 27th. Finally, Wall Street Zen upgraded shares of Co-Diagnostics from a “sell” rating to a “hold” rating in a research note on Saturday, August 22nd. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $45.00.

Co-Diagnostics Company Profile

Co-Diagnostics, Inc is a molecular diagnostics company that develops and commercializes diagnostic tests and laboratory technologies. Based in Salt Lake City, Utah, the company focuses on assays that detect genetic material from infectious diseases and other medical conditions.

The company’s core technology is its CoPrimer platform, which is designed to support the development of molecular tests using specialized primer technology. Products associated with the platform include the Logix Smart line of real-time polymerase chain reaction (PCR) assays, covering applications such as respiratory and other infectious diseases.